Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Platinum (Pt) drugs (e.g., oxaliplatin, cisplatin) are applied in the clinic worldwide for the treatment of various cancers. However, platinum-induced peripheral neuropathy (PIPN) caused by the accumulation of Pt in the peripheral nervous system limits the clinical application, whose prevention and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xi Hu, Zhijie Jiang, Longyu Teng, Hongyu Yang, Dongsheng Hong, Dongsheng Zheng, Qingwei Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	platinum peripheral neuropathy reactive oxygen species mechanism therapeutic agents nanosystems Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/3fc2826dd5a94c7f9e771266763cc593
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3fc2826dd5a94c7f9e771266763cc593
record_format	dspace
spelling	oai:doaj.org-article:3fc2826dd5a94c7f9e771266763cc5932021-11-30T18:49:45ZPlatinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems2296-889X10.3389/fmolb.2021.770808https://doaj.org/article/3fc2826dd5a94c7f9e771266763cc5932021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmolb.2021.770808/fullhttps://doaj.org/toc/2296-889XPlatinum (Pt) drugs (e.g., oxaliplatin, cisplatin) are applied in the clinic worldwide for the treatment of various cancers. However, platinum-induced peripheral neuropathy (PIPN) caused by the accumulation of Pt in the peripheral nervous system limits the clinical application, whose prevention and treatment are still a huge challenge. To date, Pt-induced reactive oxygen species (ROS) generation has been studied as one of the primary mechanisms of PIPN, whose downregulation would be feasible to relieve PIPN. This review will discuss ROS-related PIPN mechanisms including Pt accumulation in the dorsal root ganglia (DRG), ROS generation, and cellular regulation. Based on them, some antioxidant therapeutic drugs will be summarized in detail to alleviate the Pt-induced ROS overproduction. More importantly, we focus on the cutting-edge nanotechnology in view of ROS-related PIPN mechanisms and will discuss the rational fabrication of tailor-made nanosystems for efficiently preventing and treating PIPN. Last, the future prospects and potential breakthroughs of these anti-ROS agents and nanosystems will be briefly discussed.Xi HuXi HuZhijie JiangZhijie JiangLongyu TengLongyu TengHongyu YangHongyu YangDongsheng HongDongsheng HongDongsheng ZhengDongsheng ZhengQingwei ZhaoQingwei ZhaoFrontiers Media S.A.articleplatinumperipheral neuropathyreactive oxygen speciesmechanismtherapeutic agentsnanosystemsBiology (General)QH301-705.5ENFrontiers in Molecular Biosciences, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	platinum peripheral neuropathy reactive oxygen species mechanism therapeutic agents nanosystems Biology (General) QH301-705.5
spellingShingle	platinum peripheral neuropathy reactive oxygen species mechanism therapeutic agents nanosystems Biology (General) QH301-705.5 Xi Hu Xi Hu Zhijie Jiang Zhijie Jiang Longyu Teng Longyu Teng Hongyu Yang Hongyu Yang Dongsheng Hong Dongsheng Hong Dongsheng Zheng Dongsheng Zheng Qingwei Zhao Qingwei Zhao Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
description	Platinum (Pt) drugs (e.g., oxaliplatin, cisplatin) are applied in the clinic worldwide for the treatment of various cancers. However, platinum-induced peripheral neuropathy (PIPN) caused by the accumulation of Pt in the peripheral nervous system limits the clinical application, whose prevention and treatment are still a huge challenge. To date, Pt-induced reactive oxygen species (ROS) generation has been studied as one of the primary mechanisms of PIPN, whose downregulation would be feasible to relieve PIPN. This review will discuss ROS-related PIPN mechanisms including Pt accumulation in the dorsal root ganglia (DRG), ROS generation, and cellular regulation. Based on them, some antioxidant therapeutic drugs will be summarized in detail to alleviate the Pt-induced ROS overproduction. More importantly, we focus on the cutting-edge nanotechnology in view of ROS-related PIPN mechanisms and will discuss the rational fabrication of tailor-made nanosystems for efficiently preventing and treating PIPN. Last, the future prospects and potential breakthroughs of these anti-ROS agents and nanosystems will be briefly discussed.
format	article
author	Xi Hu Xi Hu Zhijie Jiang Zhijie Jiang Longyu Teng Longyu Teng Hongyu Yang Hongyu Yang Dongsheng Hong Dongsheng Hong Dongsheng Zheng Dongsheng Zheng Qingwei Zhao Qingwei Zhao
author_facet	Xi Hu Xi Hu Zhijie Jiang Zhijie Jiang Longyu Teng Longyu Teng Hongyu Yang Hongyu Yang Dongsheng Hong Dongsheng Hong Dongsheng Zheng Dongsheng Zheng Qingwei Zhao Qingwei Zhao
author_sort	Xi Hu
title	Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
title_short	Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
title_full	Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
title_fullStr	Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
title_full_unstemmed	Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
title_sort	platinum-induced peripheral neuropathy (pipn): ros-related mechanism, therapeutic agents, and nanosystems
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/3fc2826dd5a94c7f9e771266763cc593
work_keys_str_mv	AT xihu platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT xihu platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT zhijiejiang platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT zhijiejiang platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT longyuteng platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT longyuteng platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT hongyuyang platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT hongyuyang platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT dongshenghong platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT dongshenghong platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT dongshengzheng platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT dongshengzheng platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT qingweizhao platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems AT qingweizhao platinuminducedperipheralneuropathypipnrosrelatedmechanismtherapeuticagentsandnanosystems
_version_	1718406317485326336

Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Ejemplares similares